News & Updates

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

19 Feb 2025

Patients with metastatic renal cell carcinoma (RCC) may gain significantly better survival outcomes with lenvatinib therapy than with other tyrosine kinase inhibitors (TKIs), suggests a study.

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

19 Feb 2025

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

In the first-line treatment of patients with EGFR-mutated locally advanced or metastatic non–small-cell lung cancer (NSCLC), the novel third-generation EGFR tyrosine kinase inhibitor rezivertinib yields superior overall efficacy and progression-free survival (PFS) when compared with gefitinib, with no new safety signals, according to the phase III REZOR trial.

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

14 Feb 2025

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

For patients with resectable esophageal adenocarcinoma, survival outcomes appear to be better with perioperative chemotherapy with FLOT vs preoperative chemoradiotherapy, according to a phase III study.

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

13 Feb 2025

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025 by

When treating patients with locally advanced esophageal squamous cell carcinoma (ESCC) in the neoadjuvant setting, chemoradiotherapy with or without sintilimab results in significantly higher pathological complete response (pCR) rates compared with chemotherapy plus sintilimab, according to preliminary data from the phase III SCIENCE trial from China.

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

12 Feb 2025

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025 by

Occurring in up to 20 percent of breast cancers, HER2 overexpression is linked to high disease recurrence and poor survival outcomes. At the Hong Kong Breast Cancer Foundation (HKBCF) Annual Breast Cancer Updates 2024 meeting, Professor Matteo Lambertini from University of Genova, Italy, discussed the benefits of adding pertuzumab to trastuzumab and chemotherapy in managing HER2-positive (HER2+) early breast cancer (EBC), while a real-world case was shared by Dr Josephine Tsang from Queen Mary Hospital, Hong Kong.

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

12 Feb 2025

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

12 Feb 2025 by

A 59-year-old female was referred to our clinic in 2017 with a confirmed diagnosis of chronic lymphocytic leukaemia (CLL). Her Eastern Cooperative Oncology Group performance status was 0. She had dyslipidaemia for which she was receiving statin therapy, but no other remarkable history.

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

12 Feb 2025

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

Patients with hepatocellular carcinoma (HCC) who are receiving treatment with the combination of atezolizumab plus bevacizumab may be at risk of variceal bleeding, particularly those with a low platelet count, portal vein invasion, history of gastrointestinal bleeding, and varices needing treatment, as shown in a retrospective study.

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

10 Feb 2025

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025 by

Dual immunotherapy with checkpoint inhibitors nivolumab and ipilimumab works better to slow disease progression in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) when compared with single-agent nivolumab, as shown in the phase III CheckMate 8HW trial.

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

09 Feb 2025

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

08 Feb 2025 by

A 45-year-old premenopausal female who was otherwise healthy presented in September 2020 with a lump, which was the size of an egg yolk, in her right breast. Diagnostic workup revealed multiple irregularly edged masses in the right breast, with the largest located in the upper outer quadrant measuring approximately 37 x 21 mm, and multiple enhanced lymph nodes (LNs) of approximately 13 x 10 mm in the right armpit. Biopsy of the breast mass and LNs showed invasive HER2-positive and hormone receptor (HR)–positive (both oestrogen receptor– and progesterone receptor–positive) ductal carcinoma, with a Ki-67 level of 20 percent. The patient was diagnosed with HER2-positive breast cancer (BC; cT2NxM0).

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

08 Feb 2025

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

07 Feb 2025 by

A 43-year-old premenopausal female presented with a left breast mass in April 2022. She had good past health and an excellent performance status. A biopsy showed invasive ductal carcinoma (IDC) that was weakly hormone receptor–positive (oestrogen receptor [ER], 4/8; progesterone receptor [PR], 3/8) and human epidermal growth factor receptor-2–negative (HER2-) with a Ki-67 proliferation index of 60 percent. A PET-CT scan performed at the time of initial diagnosis showed no distant metastases, and the tumour was clinically staged as cT2N0M0. Immediate resection was not feasible as the growth was attached to the underlying muscle.

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

07 Feb 2025

News & Updates

Filter by Specialty:

Specialty:

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

Lenvatinib outdoes other TKIs in improving survival in metastatic RCC

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Rezivertinib bests gefitinib in first-line treatment of advanced EGFR-mutant NSCLC

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Perioperative chemo with FLOT confers survival advantage in esophageal cancer

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Esophageal cancer responds well to neoadjuvant chemoradiotherapy plus immunotherapy

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

Dual HER2 blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

First-line fixed-duration BTK inhibitor plus BCL-2 inhibitor in a patient with CLL

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

Certain HCC patients on atezolizumab–bevacizumab combo at risk of variceal bleeding

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

CheckMate 8HW makes case for doubling up on checkpoint inhibitors for mCRC

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

1-year extended adjuvant therapy in a patient with HER2- and HR-positive breast cancer without pCR after surgery

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC

Use of a Trop-2–targeted ADC in a heavily pretreated patient with unresectable advanced TNBC